CD44 and central nervous system cancer: Glioma patients with IDH1 mutation have median OS three times longer than those without (27), codeletion of 1p and 19q is associated with better survival rates in glioma (29), and thus, low CD44 expression patients with glioma may have better clinical outcomes.